Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205776 | 0.87 | LMNA (0.43) | SMN1; SMN2LMNAPOLBKMT2ATRPA1 | |
| SCHEMBL18256643 | 0.83 | ADORA2B (0.56) | SMN1; SMN2LMNAPOLB | |
| SCHEMBL18256710 | 0.83 | KMT2A (0.51) | LMNAPOLBKMT2ATRPA1HIF1A | |
| SCHEMBL18256623 | 0.83 | KMT2A (0.43) | LMNAPOLBKMT2ATRPA1HIF1A | |
| SCHEMBL18256066 | 0.80 | KMT2A (0.60) | SMN1; SMN2LMNAPOLBKMT2AALDH1A1 | |
| SCHEMBL20205786 | 0.79 | KMT2A (0.46) | LMNAPOLBKMT2ATRPA1HIF1A | |
| SCHEMBL18256624 | 0.78 | CNOT7 (0.39) | SMN1; SMN2LMNAALDH1A1NPSR1 | |
| SCHEMBL20011104 | 0.77 | LMNA (0.62) | SMN1; SMN2LMNAPDE1APDE1BPDE1C | |
| Isbufylline SCHEMBL678978 | 0.76 | LMNA (0.78) | SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL19601332 | 0.74 | LMNA (0.48) | SMN1; SMN2LMNAPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| WO-2016184313-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | SMN1; SMN2 1801/4885LMNA 2283/4885PDE1A 124/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | SMN1; SMN2 1801/4885LMNA 2283/4885PDE1A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.